BenevolentAI looks to artificial intelligence for speedy development of in-licensed drugs

BenevolentAI has reached exclusive license agreement with Janssen for clinical-stage drug candidates.

A key ambition of BenevolentAI is to utilize artificial intelligence in revolutionizing the drug development process. Now, with a licensing agreement with Janssen, it is one significant step closer to realizing that dream.

With assistance from Johnson & Johnson Innovation's Centre in London, the British AI company has acquired an undisclosed number of novel clinical stage drug candidates, together with their related patents. The company used its AI platform to evaluate the potential of these small molecule compounds and found some could be promising candidates for hard-to-treat diseases.

“The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases,” said BenevolentBio’s CEO Jackie Hunter. “Securing these novel clinical drug candidates perfectly aligns with our strategy of developing first-in-class and best-in-class stratified medicines to help patients with high unmet needs.”

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

BenevolentAI was relaunched in 2013 from what was known as Stratified Medical. It was founded by the tech-savvy management team of Proximagen, the drug R&D subsidiary of Upsher-Smith Laboratories. To them, it is quite tempting what AI potentially can do to accelerate biomedical discoveries by uniting technology and bioscience.

“A new scientific paper is published every 30 seconds and there are 10,000 updates to PubMed every day,” James Chandler, a media aide for the company told FierceCRO. “It is impossible for humans alone to process all of the complex information potentially available to them for the advancement of scientific research.” As a consequence, only a small proportion of scientific information generated worldwide becomes “useable” knowledge.

That’s the kind of problems companies like BenevolentAI want to solve—by harnessing the power of AI to process massive amount of scientific information and provide scientists with the insight and analytical tools they need to dramatically speed up drug discovery.

Actually, that process has already been proven to be doable. Earlier this year, Insilico Medicine, another bioinformatics firm which has set up an entire Pharma.AI division focused on using AI for drug discovery, published an article in Molecular Pharmaceutics about how to teach AI to predict potential therapeutic use of new drugs even before they’re tested. The process also involves taking in huge amounts of data, but from experiments involving established drugs. The model exhibited meaningful accuracy in identifying the drugs' potential to be re-purposed for other clinical applications. Even if it’s just one step forward, the company predicted that AI could rapidly accelerate the preclinical stage of drug development.

BenevolentAI's deal with Janssen gives it the sole right to develop, manufacture and commercialize those novel drug candidates in all indications, and the company says it intends to begin Phase IIb clinical trials in mid-2017.

Although it is currently focusing on the application of its technology on human meds development, Chandler said BenevolentAI is also beginning to seek ways to expand into other area of scientific discovery such as veterinary medicine, nutraceuticals, materials science and agro technology. 

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.